TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from SkinBioTherapeutics ( (GB:SBTX) ) is now available.
SkinBioTherapeutics reported significant growth in its full-year results for 2025, with revenues increasing by 284% to £4.6 million, driven by direct sales and royalty revenues from its AxisBiotix™ and Dermatonics products. The company finalized a commercial agreement with Croda and launched Zenakine™ in the global cosmetics industry, while also expanding its retail presence through an exclusive agreement with Superdrug Stores plc. The acquisitions of Bio-Tech Solutions and Dermatonics have bolstered its manufacturing capabilities and financial performance, positioning the company for continued growth in the skin health industry.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.
SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock’s score remains low.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, leveraging its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s translational dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and gut-skin axis food supplements. It has partnerships, such as with Croda plc, and sells products directly and through retailers like Superdrug Stores plc.
Average Trading Volume: 887,027
Technical Sentiment Signal: Buy
Current Market Cap: £43.02M
For detailed information about SBTX stock, go to TipRanks’ Stock Analysis page.